FDA approves Hympavzi for hemophilia

Published Date: 16 Oct 2024

The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

2.

Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.

3.

Hospitalization and mortality rates are associated with exposure to the omicron variant of COVID-19 in patients with solid cancer.

4.

AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancer

5.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot